Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients

Trial Profile

Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs PAN 301 1 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Sponsors Panacea Pharmaceuticals
  • Most Recent Events

    • 18 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
    • 30 Jan 2017 New trial record
    • 17 Jan 2017 According to a Panacea Pharmaceuticals media release, first patient has been enrolled and dosed in this trial. Centres of this trial located in Alabama, California, Nebraska and South Carolina. Luke Nordquist is Lead Principal Investigator for the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top